RETIFANLIMAB-DLWR

RETIFANLIMAB-DLWR was reported 72 times

These side effects are most commonly reported by patients taking RETIFANLIMAB-DLWR:

# Side effect Count
0 OFF LABEL USE 25
1 DISEASE PROGRESSION 11
2 ANAL SQUAMOUS CELL CARCINOMA 6
3 ANAL CANCER 5
4 DEATH 4
5 MALIGNANT NEOPLASM PROGRESSION 4
6 NAUSEA 4
7 ANAEMIA 3
8 CONDITION AGGRAVATED 3
9 DECREASED APPETITE 3
10 MALAISE 3
11 NEUROPATHY PERIPHERAL 3
12 PRODUCT DOSE OMISSION ISSUE 3
13 THROMBOCYTOPENIA 3
14 GENERAL PHYSICAL HEALTH DETERIORATION 2
15 INTESTINAL OBSTRUCTION 2
16 METASTASES TO LIVER 2
17 NASOPHARYNGITIS 2
18 NEUTROPENIA 2
19 PLATELET COUNT DECREASED 2
20 THERAPY CESSATION 2
21 TREATMENT NONCOMPLIANCE 2
22 ALOPECIA 1
23 ANAL CANCER RECURRENT 1
24 ARTHRALGIA 1
25 ASTHENIA 1
26 AUTOIMMUNE THYROIDITIS 1
27 BLINDNESS 1
28 BONE PAIN 1
29 BREAST CANCER 1
30 CELLULITIS 1
31 COLOSTOMY INFECTION 1
32 COVID-19 1
33 COVID-19 PNEUMONIA 1
34 DEPRESSION 1
35 DIABETES MELLITUS 1
36 DIARRHOEA 1
37 DRUG ERUPTION 1
38 DRUG HYPERSENSITIVITY 1
39 DYSSTASIA 1
40 ELECTROLYTE IMBALANCE 1
41 FATIGUE 1
42 FEELING ABNORMAL 1
43 GAIT DISTURBANCE 1
44 GASTROINTESTINAL DISORDER 1
45 GRAVES^ DISEASE 1
46 HEPATIC ENZYME INCREASED 1
47 HOSPITALISATION 1
48 HYPERSENSITIVITY 1
49 HYPERTHYROIDISM 1
50 HYPOAESTHESIA 1
51 HYPOAESTHESIA ORAL 1
52 HYPOGLYCAEMIA 1
53 ILLNESS 1
54 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 1
55 INFUSION RELATED REACTION 1
56 INFUSION SITE INFECTION 1
57 JOINT LOCK 1
58 MOBILITY DECREASED 1
59 NEUROENDOCRINE CARCINOMA OF THE SKIN 1
60 NO ADVERSE EVENT 1
61 OEDEMA PERIPHERAL 1
62 PLATELET COUNT ABNORMAL 1
63 POLYNEUROPATHY 1
64 PRODUCT STORAGE ERROR 1
65 PRODUCT USE IN UNAPPROVED INDICATION 1
66 PSORIASIS 1
67 PSYCHOTIC DISORDER 1
68 SECONDARY ADRENOCORTICAL INSUFFICIENCY 1
69 SKIN ULCER 1
70 STRESS 1
71 THYROIDITIS 1
72 URINARY TRACT INFECTION 1
73 URTICARIA 1
74 VOMITING 1
75 WEIGHT DECREASED 1